Kymera Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
KYMR Nasdaq 2830 www.kymeratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kymera Therapeutics, Inc.

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Jun 30th, 2025 7:32 am
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - Jun 28th, 2025 2:16 am
Kymera’s partnerships with Sanofi and Gilead drive value - Jun 27th, 2025 8:19 am
Kymera Therapeutics Announces Pricing of $250 Million Public Offering - Jun 26th, 2025 9:56 pm
Kymera weakness a buying opportunity, says Stifel - Jun 26th, 2025 8:45 am
Morning Movers: General Mills dips following fourth quarter report - Jun 26th, 2025 7:06 am
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - Jun 26th, 2025 6:40 am
Kymera Therapeutics Announces Proposed Public Offering - Jun 25th, 2025 2:05 pm
Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal - Jun 25th, 2025 11:28 am
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi - Jun 25th, 2025 6:07 am
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update - Jun 25th, 2025 5:05 am
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Jun 25th, 2025 5:00 am
Kymera Therapeutics Stock Earns 92 RS Rating - Jun 6th, 2025 1:13 pm
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Jun 5th, 2025 2:16 pm
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - Jun 3rd, 2025 9:14 am
Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says - Jun 3rd, 2025 9:06 am
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday - Jun 3rd, 2025 12:22 am
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response - Jun 2nd, 2025 8:29 am
Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster. - Jun 2nd, 2025 5:44 am
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Jun 2nd, 2025 5:00 am